{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:53:24Z","timestamp":1785873204055,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Department of Health of Zhejiang Province","doi-asserted-by":"publisher","award":["2019RC302"],"award-info":[{"award-number":["2019RC302"]}],"id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Plan Project of Jinhua Municipal Central Hospital","award":["JY2020-6-06"],"award-info":[{"award-number":["JY2020-6-06"]}]},{"name":"Science Foundation, Science and Technology Bureau of Jinhua, Zhejiang Province, China","award":["2018-3-011"],"award-info":[{"award-number":["2018-3-011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04905-3","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:57:01Z","timestamp":1778507821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of dual biologics or combination therapy with JAK inhibitors in refractory inflammatory bowel disease: a retrospective single-center real-world study from China"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiao-Jiao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Li","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4905_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/CM9.0000000000003542","volume":"138","author":"J Wan","year":"2025","unstructured":"Wan J, Zhou J, Wang Z, Liu D, Zhang H, Xie S, et al. Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years. Chin Med J (Engl). 2025;138:763\u201376.","journal-title":"Chin Med J (Engl)"},{"key":"4905_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.gtc.2023.09.005","volume":"53","author":"N Harpaz","year":"2024","unstructured":"Harpaz N, Itzkowitz SH. Pathology and Clinical Significance of Inflammatory Bowel Disease-Associated Colorectal Dysplastic Lesions. Gastroenterol Clin North Am. 2024;53:133\u201354.","journal-title":"Gastroenterol Clin North Am"},{"key":"4905_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403:1177\u201391.","journal-title":"Lancet"},{"key":"4905_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3748\/wjg.v30.i1.50","volume":"30","author":"AR Srinivasan","year":"2024","unstructured":"Srinivasan AR. Treat to target in Crohn\u2019s disease: A practical guide for clinicians. World J Gastroenterol. 2024;30:50\u201369.","journal-title":"World J Gastroenterol"},{"key":"4905_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571\u201384.","journal-title":"Lancet"},{"key":"4905_CR6","doi-asserted-by":"crossref","unstructured":"Lee KE, Sizemore JA, Kim G, Shen B, Sands BE. Impact of Biologics and Small Molecule Agents on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review. Dis Colon Rectum. 2024.","DOI":"10.1097\/DCR.0000000000003222"},{"key":"4905_CR7","doi-asserted-by":"crossref","unstructured":"Wetwittayakhlang P, Bessissow T, Lakatos PL. Novel and emerging drugs for the treatment of Crohn\u2019s disease: a review of phase II and III trials. Expert Opin Emerg Drugs. 2024:1\u201316.","DOI":"10.1080\/14728214.2024.2303116"},{"key":"4905_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"4905_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohns Colitis. 2020;14:4\u201322.","journal-title":"J Crohns Colitis"},{"key":"4905_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/ibd\/izac275","volume":"30","author":"JP Gisbert","year":"2024","unstructured":"Gisbert JP, Parody-Rua E, Chaparro M. Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review. Inflamm Bowel Dis. 2024;30:292\u2013302.","journal-title":"Inflamm Bowel Dis"},{"key":"4905_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","volume":"16","author":"RP Hirten","year":"2018","unstructured":"Hirten RP, Iacucci M, Shah S, Ghosh S, Colombel JF. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. Clin Gastroenterol Hepatol. 2018;16:1374\u201384.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4905_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.dld.2023.06.009","volume":"56","author":"B Barberio","year":"2024","unstructured":"Barberio B, Gracie DJ, Black CJ, Ford AC. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis. Dig Liver Dis. 2024;56:7\u201314.","journal-title":"Dig Liver Dis"},{"key":"4905_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.cgh.2020.02.017","volume":"19","author":"L Kwapisz","year":"2021","unstructured":"Kwapisz L, Raffals LE, Bruining DH, Pardi DS, Tremaine WJ, Kane SV, et al. Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2021;19:616\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4905_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/apt.15719","volume":"51","author":"E Yang","year":"2020","unstructured":"Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;51:1031\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"4905_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.crohns.2009.12.001","volume":"4","author":"W Miehsler","year":"2010","unstructured":"Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, et al. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221\u201356.","journal-title":"J Crohns Colitis"},{"key":"4905_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0043-1762557","volume":"37","author":"H Williams","year":"2024","unstructured":"Williams H, Steinhagen RM. Historical Perspectives: Malignancy in Crohn\u2019s Disease and Ulcerative Colitis. Clin Colon Rectal Surg. 2024;37:5\u201312.","journal-title":"Clin Colon Rectal Surg"},{"key":"4905_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","volume":"48","author":"WJ Sandborn","year":"2018","unstructured":"Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, et al. Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"4905_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","volume":"42","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn\u2019s Disease: An Integrated Analysis of Phase II\/III Clinical Development Programs. Drug Saf. 2019;42:751\u201368.","journal-title":"Drug Saf"},{"key":"4905_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.13001","volume":"41","author":"R Khanna","year":"2015","unstructured":"Khanna R, Zou G, D\u2019Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity. Aliment Pharmacol Ther. 2015;41:77\u201386.","journal-title":"Aliment Pharmacol Ther"},{"key":"4905_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet L, Panes J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14:348\u201354. e17.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4905_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","volume":"13","author":"A Sturm","year":"2019","unstructured":"Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13:273\u201384.","journal-title":"J Crohns Colitis"},{"key":"4905_CR22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","volume":"15","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, et al. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021;15:1120\u20139.","journal-title":"J Crohns Colitis"},{"key":"4905_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12664-023-01508-8","volume":"43","author":"AT Elford","year":"2024","unstructured":"Elford AT, Ardalan Z, Simkin P, Christensen B. Comprehensive review and update of stricturing Crohn\u2019s disease. Indian J Gastroenterol. 2024;43:64\u201377.","journal-title":"Indian J Gastroenterol"},{"key":"4905_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/ibd\/izad032","volume":"30","author":"R Liu","year":"2024","unstructured":"Liu R, Li Z, Ye L, Hu J, Tang J, Chen B, et al. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn\u2019s Disease on Ustekinumab: A Nationwide Real-World Study. Inflamm Bowel Dis. 2024;30:45\u201352.","journal-title":"Inflamm Bowel Dis"},{"key":"4905_CR25","doi-asserted-by":"publisher","first-page":"1188751","DOI":"10.3389\/fphar.2023.1188751","volume":"14","author":"K Huang","year":"2023","unstructured":"Huang K, Liu J, Xia W, Tian C, Yao L, Cao Q, et al. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China. Front Pharmacol. 2023;14:1188751.","journal-title":"Front Pharmacol"},{"key":"4905_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/ibd\/izx110","volume":"24","author":"LCT Buer","year":"2018","unstructured":"Buer LCT, Hoivik ML, Warren DJ, Medhus AW, Moum BA. Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflamm Bowel Dis. 2018;24:997\u20131004.","journal-title":"Inflamm Bowel Dis"},{"key":"4905_CR27","doi-asserted-by":"crossref","unstructured":"Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A et al. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. J Crohns Colitis. 2020:jjaa149.","DOI":"10.1093\/ecco-jcc\/jjaa149"},{"key":"4905_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","volume":"17","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Loeuille D, Peyrin-Biroulet L. Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy. Clin Gastroenterol Hepatol. 2019;17:794\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4905_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1751-2980.12867","volume":"21","author":"K Glassner","year":"2020","unstructured":"Glassner K, Oglat A, Duran A, Koduru P, Perry C, Wilhite A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020;21:264\u201371.","journal-title":"J Dig Dis"},{"key":"4905_CR30","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, et al. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20:e361\u201379.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4905_CR31","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2\u2009+\u2009T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68:814\u201328.","journal-title":"Gut"},{"key":"4905_CR32","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","volume":"22","author":"JF Colombel","year":"2024","unstructured":"Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, et al. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn\u2019s Disease (EXPLORER). Clin Gastroenterol Hepatol. 2024;22:1487\u201396. e12.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04905-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:02:29Z","timestamp":1783303349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04905-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4905"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04905-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Approval no. 2024-02), and was performed in compliance to the Declaration of Helsinki. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}